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Abstract CD39 is the cell surface-located prototypic
member of the ecto-nucleoside triphosphate diphosphohy-
drolase (E-NTPDase) family. Biological actions of CD39
are a consequence (at least in part) of the regulated
phosphohydrolytic activity on extracellular nucleotides.
This ecto-enzymatic cascade in tandem with CD73 (ecto-
5’-nucleotidase) also generates adenosine and has major ef-
fects on both P2 and adenosine receptor signalling. Despite
the early recognition of CD39 as a B lymphocyte activation
marker, little is known of the role of CD39 in humoral or
cellular immune responses. There is preliminary evidence to
suggest that CD39 may impact upon antibody affinity mat-
uration. Pericellular nucleotide/nucleoside fluxes caused by
dendritic cell expressed CD39 are also involved in the
recruitment, activation and polarization of naïve T cells. We
have recently explored the patterns of CD39 expression and
the functional role of this ecto-nucleotidase within quiescent
and activated T cell subsets. Our data indicate that CD39,
together with CD73, efficiently distinguishes T regulatory
cells (Treg) from other resting or activated T cells in mice
(and humans). Furthermore, CD39 serves as an integral
component of the suppressive machinery of Treg, acting, at
least in part, through the modulation of pericellular levels of
adenosine. We have also shown that the coordinated
regulation of CD39/CD73 expression and of the adenosine
receptor A2A activates an immunoinhibitory loop that
differentially regulates Th1 and Th2 responses. The in vivo
relevance of this network is manifest in the phenotype of
Cd39-null mice that spontaneously develop features of
autoimmune diseases associated with Th1 immune devia-
tion. These data indicate the potential of CD39 and
modulated purinergic signalling in the co-ordination of
immunoregulatory functions of dendritic and Treg cells.
Our findings also suggest novel therapeutic strategies for
immune-mediated diseases.
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Abbreviations
ACR apyrase conserved regions
ATPDase ATP diphosphohydrolase
DC dendritic cell
EC endothelial cell
E-NTPDase ecto-nucleoside triphosphate
diphosphohydrolase
IL interleukin
LC Langerhans cells
NPP nucleotide pyrophosphatase/
phosphodiesterase
Treg T regulatory cells
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Our research interests have been in the purinergic modula-
tion ofvascular inflammatoryand cellular immuneresponses
in transplantation settings [1, 2]. It is generally accepted that
extracellular nucleotides [e.g., ATP, uridine triphosphate
(UTP), adenosine diphosphate (ADP)], and the derivative
nucleosides (e.g., adenosine from ATP), are released in a
regulated manner by most all cells to provide the primary
components for purinergic responses [3]. High levels of
ATP may be released by CD4
+ and CD8
+ T cells upon
stimulation with Con A or anti-CD3 mAb and serve to
activate cells [4]. Importantly, ATP [or uridine diphosphate
(UDP)] stimulation of monocytes, lymphocytes and endo-
thelium induces largely proinflammatory responses, such as
the release of interleukin (IL)-1 (or IL-8) [4–6]. On
dendritic cells (DC), exposure to extracellular ATP induces
migration and differentiation to drive cellular immune
responses [7]. Adenosine is also recognized as a bioactive
agent in vascular inflammatory states, with effects mediated
on both vascular cells and leukocytes [8]. In addition,
adenosine has known anti-thrombotic effects, modulates the
expression of anti-apoptotic genes and is immunosuppres-
sive [9]. Adenosine is constitutively present in the extracel-
lular space at low concentrations, but under metabolically
stressful and hypoxic conditions, the levels rise dramatically
[10]. Primary release of the mediator could occur ab initio,
or this might follow conversion of released nucleotides to
adenosine (see later).
The nucleotide/nucleoside mediators alluded to above
bind specific purinergic receptors that comprise the second
requirement for this complicated signalling network. Al-
most all cells carry cell-surface type 2 purinergic (P2)
receptors for nucleotides and adenosine or type 1 purinergic
(P1) receptors [11]. There are seven ionotropic (P2X), at
least eight metabotropic (P2Y) and four adenosine receptor
subtypes that have been identified and characterized to date
[12]. Multiple P2X and P2Y receptor subtypes are ex-
pressed by monocytes and dendritic cells, whereas lympho-
cytes express only P2Y receptors [11]. These various
receptors operate in both auto- and paracrine loops and
are considered to play a complex, important role in the
regulation of vascular and immune cell-mediated responses.
Depending on the P2 or adenosine receptor subtype, the
cell types and signalling pathway involved, these receptors
might preferentially trigger and mediate short-term (acute)
processes that affect metabolism, adhesion, activation or
migration. However, purinergic signalling also has pro-
found impacts upon other more protracted reactions,
including cell proliferation, differentiation and apoptosis,
such as seen in several chronic inflammatory states [12].
These mechanisms could be also implicated in immune
memory [9, 13].
The third, and final, component of purinergic signalling
systems comprises ecto-nucleotidases [2, 14]. These ecto-
enzymes hydrolyze extracellular nucleotides to generate
nucleosides that in turn activate adenosine receptors, often
with opposing effects to those seen with P2-mediated effects.
Within the past decade, ecto-nucleotidases belonging to
several enzyme families have been discovered, cloned and
functionally characterized by pharmacological means.
In this review, we will focus on CD39, the prototype of
the ecto-nucleoside triphosphate diphosphohydrolase (E-
NTPDase) family (EC 3.6.1.5) [15, 16]. These proteins
comprise a group of ecto-enzymes that hydrolyze extracel-
lular nucleoside tri- and diphosphates. The ecto-nucleotidase
chain or cascade, as initiated by NTPDases, is terminated by
ecto-5′-nucleotidase (CD73; EC 3.1.3.5) [2, 17]. Together,
ecto-5′-nucleotidase and adenosine deaminase (ADA; EC
3.5.4.4), another ecto-enzyme that is involved in purine
salvage pathways by converting adenosine to inosine,
closely regulate local and pericellular extracellular concen-
trations of adenosine [2]. Most notably, however, in many
tissues and cells, NTPDases also comprise dominant parts
of a complex cell surface-located nucleotide hydrolyzing
and interconverting machinery. Such ensembles also
include the ecto-nucleotide pyrophosphatase phosphodies-
terases (E-NPPs), NAD-glycohydrolases, CD38/NADase
activity, alkaline phosphatases, diadenosine polyphosphate
hydrolases, adenylate kinase, nucleoside diphosphate
kinase, and potentially ecto-F1-Fo ATP synthases [2].
Many aspects of these ecto-nucleotidase families and
detailed expositions of structure/function relationships of
the E-NTPDases and their role in the vasculature and
nervous systems have been reviewed recently. The inter-
ested reader is referred to the recent special issue of
Purinergic Signalling entitled “Ecto-nucleotidases” (PUSI
2, 2: 2006). This review will address only the immunobi-
ology of CD39, focusing on T lymphocytes and alluding
briefly to co-expression of CD73 by immunosuppressive T
cell subsets.
CD39 in the immune system
Recently, almost all of the published investigative focus on
CD39 has been on the thromboregulatory properties of
CD39 with respect to platelet and endothelial activation [1].
However, CD39 was first described as a B lymphocyte
activation marker [18]. This ecto-nucleotidase is also
expressed on natural killer (NK) cells, monocytes, DC
and subsets of activated T cells [19]. The relevance of the
expression of CD39 by these cells is not yet clear.
Development of mutant mice either null for Cd39 or
where human CD39 has been over-expressed have provided
useful models to study the role of this ecto-nucleotidase in
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cell numbers [anti-CD45RA 14.8; anti-CD22.2 (Lyb-8.20;
PharMingen, San Diego CA, USA)] in unstimulated blood
and spleen have been noted to be normal (not shown).
Somewhat surprisingly, elicited IgG xenoantibody responses
to solubilized xenoantigens administered to Cd39-null mice
were found to be markedly suppressed [14]. With Dr. M.
Cascalho (Mayo Clinic, Rochester, MN, USA), we have
investigated whether Cd39-null mice are capable of
appropriate antibody responses. We have noted that Cd39-
null mice exhibit impaired B cell memory responses to T-
dependent antigens. Unexpectedly, however, these mutant
mice show a significant increase in the frequency of
somatic mutations post-immunization (not shown). These
observationssuggestthatCD39functionmaycontributetothe
affinity maturation of antibody responses and to facilitate
post-germinal center terminal B cell differentiation (M.
Cascalho et al., manuscript in preparation).
Although CD39 has been shown to be the dominant
ecto-nucleotidase expressed by NK and NK-T cells and to
impact upon cytokine production ([19]; G. Beldi, unpub-
lished), the relevance of this has not yet been fully
elucidated.
CD39 is also the major NTPDase expressed by mono-
cyte-macrophages. Upregulation of tissue factor expression
by these cells in vitro and alterations in splenic macrophage
populations in vivo have been observed in Cd39-null mice.
P2Y receptors that are impacted upon by CD39 are
critically linked to monocyte and endothelial cell respon-
siveness [22, 23]. P2Y receptors on monocytes could be
also subject to desensitization, comparable to what we have
observed in platelet P2Y1 receptors in Cd39-null mice [20].
Therefore, we were interested to observe major defects in
monocycle entry and migration into the substance of
Matrigel plugs injected into the subcutaneous tissue of
Cd39-null mice. In parallel, we also evaluated parameters
of monocyte transendothelial migration influenced by ATP
in vitro and noted failure of Cd39-null cells to migrate in
response to exogenous nucleotides. This defect could be
overcome by co-stimulation with serotonin, suggesting a
degree of P2Y receptor desensitization in Cd39-null
monocytes [14, 24].
Ecto-enzymes, specifically ecto-nucleotidases, are known
to play an important role in leukocyte trafficking but this
complex area will not be dealt with here (for an excellent
review on this topic, see [25]). However, CD39 has been
recognized as a critical control point in the regulation of
leukocyte accumulation within hypoxic tissues and a
sixfold increase in CD39/CD73 tandem functioning in the
setting of hypoxia has been demonstrated [26, 27].
Langerhans cells (LC) are members of the DC family of
antigen-presenting cells residing in the skin. NTPDase1
enzymatic function on antigen presenting DC is involved in
the recruitment, activation and polarization of naïve T cells.
Mizumoto et al. established that LC from the Cd39-null
mice do not hydrolyze ATP and ADP, unlike wild-type cells
[28]. Cd39-null DC are also markedly unresponsive to ATP
and are susceptible to cell death, but only after prolonged
exposure to nucleotides [28].
Mutant mice null for Cd39 have amplified inflammatory
responses to irritant chemicals. In these Cd39-null mice,
there are major defects in dendritic cell formation, antigen
presentation and T cell responses to haptens. These result in
markedly attenuated responses to contact allergens in type
IV hypersensitivity cutaneous responses that are also seen
in inflammatory bowel disease models following haptenic
stimulation (not shown).
These data suggest that Cd39 expression is required for
optimal stimulation of hapten-reactive T cells in mice [28].
Somewhat paradoxically, CD39 also appears to function as
an additional recognition structure on haptenated target
immunocytes for HLA-A1-restricted, hapten-specific cyto-
toxic T cells [29]. Curiously, following deletion of Cd39,
LC are fully functional with respect to homing and
phenotypic maturation. However, the major defect is that
these cells appear less able to stimulate T cells. These
abnormalities are potentially also relevant to allograft
rejection processes [14]. Sequelae of these putative immune
abnormalities include the relative failure of Cd39-null mice
to reject allografts under limited co-stimulation blockade
[30]. These data indicate a previously unrecognized role of
CD39 and the effects on nucleotide-mediated signalling in
immunological responses [28].
Localization of CD39 within lipid rafts implies that this
ecto-enzyme may be involved in cell-cell contacts and
signalling [31]. Such membrane micro-domains serve as
the “message center” in which numerous signalling
molecules are concentrated and scaffolding developed
[32]. The Cd39-null DC might exhibit defective functions
because of putative defects in initiating and maintaining
cell-cell contacts. This mechanism speculatively involves
facilitating integrin associations by purinergic signals
within the “immunological synapse” and would have
parallels to the way chemokines have been implicated in
this process [33–36]. CD39 on DC and/or T cells may be
likewise translocated to the immunological synapse during
antigen presentation to facilitate intercellular signalling.
More typically, CD39 is considered to play a cellular
immunoregulatory role by hydrolyzing ATP (and perhaps
ADP) released by T cells during antigen presentation and
thereby generating adenosine, a known immunosuppressive
molecule.
Recent work has also indicated that regulatory CD4+ve
CD25+ve T cells (Treg cells) play important roles in the
suppression of immunological reactivity and maintenance
of tolerance [37, 38]. Patterns of expression of CD39 by
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nucleotides/nucleosides influence(s) the function of these
interesting cells have been a major focus of investigation in
our laboratories of late.
CD39 expression by immunosuppressive regulatory
T cells
Treg are central tothe acquisitionofimmunologicaltolerance.
Here the immune system does not mount cellular responses
against specific antigens while reactivity towards other
antigens is maintained. The precise mechanisms underlying
the acquisition of tolerance are not fully understood. Trans-
planted graft outcomes in the absence of heavy immunosup-
pression depend on consistent balances between cytopathic
effectorcellsandTreg[39]. Depletion of the cytopathic Tcell
clone has been proposed as one mechanism for the induction
of tolerance. However, it is now clear that the long-term
maintenance of tolerance is also dependent on self-perpetu-
ating immunoregulatory mechanisms that limit or constrain
alloresponses. The suppressive Treg populations are consid-
ered key to the development and maintenance of peripheral
tolerance [33, 40].
Significant deficiencies are apparent in identifying Treg.
Although traditionally defined by CD4
+CD25
+ expression,
the latter marker along with other membrane proteins such
as GITR and CTLA4 becomes non-specific and somewhat
redundant following activation. Such markers are widely
upregulated on other cells thereby losing specificity for the
Treg population. The forkhead winged transcription factor
FoxP3 is specific for Treg; however, its intracellular
location limits its usefulness in the study of this population.
Moreover, it is now apparent that CD25 does not encompass
all Treg as defined by FoxP3
+ expression [41].
Similarly, the mechanisms of Treg action are poorly
defined. Putative mechanisms of suppression by Treg
include cell-to-cell contact predominant in vitro and the
release of soluble mediators that may predominate in vivo.
As an example, IL-10 and transforming growth factor β
have been identified as soluble factors that may mediate
Treg suppression. Our recent studies and data from other
groups have indicated that adenosine is an important
mediator generated by Treg cells, and appears responsible
for, at least in part, their functions [42].
Patterns of immune expression of CD39 by Treg were
determined using standard techniques; using the Cd39-null
mouse cells as negative controls. CD3
+, CD8
+, NK1.1
+,
B220
+, CD11b
+ and CD11c
+ cells were positively selected
from spleens and lymph nodes of 8- to 10-week-old
C57BL6 mice through the use of MACS Sort magnetic
beads in MACS LS Separation columns (Miltenyi Biotec,
Bergisch Gladbach, Germany). T cells enriched for CD4
were obtained from lymph node and spleen preparations
using CD4 T cell columns (R&D Systems, Minneapolis,
MN, USA). CD4
+/CD25
+ and CD4
+/CD39
+ were positive-
ly selected using the relevant antibody and MACS Sort
magnetic beads in MACS MS Separation columns (Milte-
nyi Biotech, Bergisch Gladbach, Germany). Where indicat-
ed, the same subsets were also sorted after staining the
purified CD4
+ cells with CD25 or CD39, using the MoFlo
cell sorter (BD Biosciences, San Jose, CA, USA). In
selected experiments, CD4
+/CD25
+ cells were purified
using the murine CD4
+CD25
+ T regulatory cell isolation
kit from Miltenyi Biotech (Bergisch Gladbach, Germany).
The purity of the different cell populations was verified by
flow cytometry on FACSort (BD Biosciences, San Jose,
CA, USA). Anti-mouse and anti-human CD4, CD8, CD19,
B220, NK1.1 and CD25 were from eBiosciences (San
Diego, CA, USA), as were anti-mouse CD5, CD62L,
CD45RB, interferon (IFN)-+ and IL-4. Purified anti-mouse
CD3 and CD28 were from PharMingen (BD Biosciences,
San Diego CA, USA). Rabbit anti-mouse CD39 polyclonal
antibody was used to stain cells purified from wild-type
lymph nodes and from spleen, as described [43].
Using cells harvested from naïve C57BL6 mice, CD39
was found to be expressed by the majority of monocytes
and by subsets of lymphocytes, also inferred by gating on
forward scatter (FSC) and side scatter (SSC; not shown).
Among node-derived lymphocytes, the majority of CD39
+
cells are found in CD19
+ (or B220
+) B cells. The remaining
CD39
+ cells were shown to reside almost totally within the
CD4
+ subset (Fig. 1a). There, they consistently range from
8 to 12% of all CD4
+ cells in lymph node (and spleen).
Further characterization of resting C57BL6 lymphocytes
revealed that CD39 is selectively expressed on CD4
+/CD25
+
T cells (Fig. 1a). CD39 is consistently and abundantly
expressed in CD4
+/CD25
high T cells, while the CD4
+/
CD25
dim populations show a dichotomic expression pattern
of CD39, with ~50% of the cells positive. Less than 1% of
CD39
+ cells were found in the CD4
+/CD25
− compartment.
The majority of peripheral CD4
+/CD39
+ cells are also
CD45RB
low and mostly CD62L
low, with similar expression
patterns observed in BALB/c mice (not shown).
These results were confirmed by reverse transcription
polymerase chain reaction (RT-PCR) analysis of selected
cell populations. Both CD11b
+ and CD11c
+ cells expressed
high levels of CD39 mRNA, indicating that macrophages
and dendritic cells constitutively express CD39. Within the
T cell compartment, the highest expression levels of CD39
transcripts were found in CD4
+ cells. Gene expression
profiling of CD4
+ T cells, sorted on the basis of CD39 cell
surface expression, indicated that the CD4
+/CD39
+, but not
CD4
+/CD39
−, Tcells robustly express markers of Treg cells
[40], viz. Foxp3, CD25, GITR and CTLA-4. Further,
CD4
+/CD39
+ cells are anergic in the absence of IL-2 (not
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+/CD25
−) proliferation
with an efficacy similar to that observed with classic CD4
+/
CD25
+ Treg (S. Deaglio et al., submitted manuscript).
We have also confirmed the utility of CD39 in defining
human Treg populations as comparable patterns of CD39
antigen expression in human cells are observed. The
majority of human CD19
+ B cells express CD39; however,
within the T cell compartment CD39
+ cells are present in
the CD4
+ subset (not shown). As in the mouse, CD39 is
highly expressed in the CD4
+/CD25
high T cells, with only
Fig. 1 a Expression of CD39 on mouse lymphoid cells. Lymph node
cell suspensions were prepared from 8-week-old C57/BL6 mice and
were gated based on FSC and SSC parameters (not shown). CD4
+ cells
were gated based on CD25 expression. CD39 expression on the
different subsets is shown in the histograms (open profiles) plotted
against an irrelevant control (gray profiles). Differential expression of
CD39 on CD4
+ cells can be shown to be closely associated with CD25.
b RT-PCR analysis of foxp3 mRNA expression. This was done in
sorted cells with the following markers: Foxp3
+/CD39
+, Foxp3
+/
CD39
-, Foxp3
-/CD39
+ and Foxp3
-/CD39
-. CD4
+ cells obtained from
the Foxp3-GFP “knockin” animals that had been generated by
Mohamed Oukka and Vijay K. Kuchroo with colleagues (Ref). B
lymphocytes were used as CD39
+ control and included for comparison
(striped bars). c RT-PCR analysis of CD73 mRNA expression. This
was done in sorted cells with the following markers: Foxp3
+/CD39
+,
Foxp3
+/CD39
-, Foxp3
-/CD39
+ and Foxp3
-/CD39
-. B lymphocytes
were used as CD39
+ control and included for comparison (striped
bars). CD73 is also a useful immunophenotypic marker for Treg cells
(not shown); and when combined with CD39 provides near-concor-
dance with foxp3 expression. The Foxp3
-/CD39
+ subset does not
express CD73 and these cells resemble the memory phenotype (not
shown)
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+ within the CD4
+/CD25
dim population.
Negligible CD39 expression is found in the CD4
+/CD25
−
population (not shown). Gene expression profiling of human
CD4
+/CD39
+ T cells also confirms that these cells express
Foxp3, GITR and CD25 in a pattern analogous to that of
traditional CD4
+/CD25
+ Treg (K. Dwyer et al., submitted).
Our analysis demonstrates that CD39 expression in both
murine and human T cells is restricted to a subpopulation of
CD4
+/CD25
+ cells that expresses markers associated with T
regulatory function.
We have further examined the exact relationship between
CD39 expression and the regulatory phenotype by using T
cells from mutant mice with the green fluorescent protein
(GFP) reporter gene introduced into the endogenous Foxp3
locus [designated as “Foxp3
+(GFP
+) knockin” cells; kindly
provided for these experiments by M. Oukka and V. K.
Kuchroo, Boston, MA, USA] [44]. Four populations could
be defined by differential CD39 and Foxp3 expression:
Foxp3
+/CD39
+, Foxp3
+/CD39
− (minor population group-
ing), Foxp3
−/CD39
+ and Foxp3
−/CD39
−. These popula-
tions were sorted and gene expression profiles determined.
The GFP
+/CD39
+ fraction was shown to mirror the genetic
profile of Treg, as defined by the presence of Foxp3
transcripts in this positive control (Fig. 1b). Interestingly,
the next major subpopulation Foxp3
–/CD39
+ cells contain
T lymphocytes that are not classic Treg and yet appear to be
associated with the memory compartment (W. Gao,
manuscript in preparation; Fig. 1b).
Foxp3
+(GFP
+) Treg however were also found to co-
express the ecto-nucleotidase CD73, a unique situation
amongst T lymphocytes (Fig. 1c). Consistent with other
phenotypic data (not shown), RT-PCR analysis confirms that
Foxp3
+/CD39
+ cells have high levels of gene expression of
both CD39 and CD73 (Fig. 1b). CD73, which converts
AMP to adenosine downstream of CD39, has been indepen-
dently identified on CD25
+ (FoxP3
+) Treg and CD25
−
uncommitted primed precursor Th cells [42]. This recent
work further supports our observations that the expression of
ecto-nucleotidases and consequent adenosine generation play
a role in the mediation of some of the suppressive
capabilities of Treg cells. Hence, CD73 is co-expressed with
CD39 as a cell surface marker of murine Tregs (Fig. 1c).
Fig. 3 CD39 generation of adenosine preferentially regulates Th1
immune responses. a 3H-thymidine incorporation of CD4
+ T cells
purified from WT mice as polarized towards a Th1 or a Th2 phenotype
for 5 days. The selective adenosine A2A agonist ATL146e was added
after 3 days of culture. Data are expressed as % of inhibition and are the
mean of duplicates; error bars represent the SEM of three independent
experiments. b CD4
+ T cells were purified from Cd39-null (filled
histograms)o rW T( open histograms) mice and polarized towards a Th1
phenotype. The mRNA was extracted at day 3 and assayed for IFN-g
(left panel) by RT-PCR. Data are representative of more than four
independent experiments. c CD4
+ T cells were purified from Cd39-null
(filled histograms)o rW T( open histograms) mice and polarized towards
a Th1 phenotype. The indicated adenosine receptor agonists and
antagonists were added at the beginning of the experiment (left panel).
d This panel shows the effects of apyrase on IFN-g production by Cd39-
null CD4
+ T cells polarized towards a Th1 phenotype. For these
experiments, mRNAwas extracted at day 3 and assayed for IFN-g (RT-
PCR). Representative data are shown from three independent experi-
ments for each. e Representative images of Cd39-null mouse on C57BL/
6/129 SVJ (upper panel) or BALB/c backgrounds (lower panel)
manifesting alopecia. Histology of skin samples obtained from Cd39-
null mice affected by alopecia. Uninvolved skin areas from the same
animals as well as samples from WT mice were used for comparison.
Biopsies were fixed and stained for CD4 cells. Original magnifications:
×10 for the upper middle panel, ×40 for the upper right and ×20 for the
lower panels. f Skin samples were obtained from Cd39-null mice
affected by alopecia, the tissue homogenized and mRNA extracted.
Cytokine profiling was performed by RT-PCR, using a preamplification
technique. Uninvolved skin from the same animal or a matched WT
mouse used as controls. Representative data are from three animals
b
Fig. 2 Schematic representation
of Treg markers. The cellular
phenotype of these suppressive
T cells can be defined by
FoxP3
+/CD39
+/CD73
+ expres-
sion. Phosphohydrolysis of ex-
tracellular nucleotides by CD39
and CD73 generates adenosine,
which exerts a component of the
immunosuppressive effect
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Tregs from mutant mice deficient in CD39 have impaired
regulatory function manifesting as a 50% decrease in the
ability of Cd39-null Tregs to modulate effector T cell
function in vitro and in vivo. These results indicate that
CD39 expressed by Treg is the major and rate limiting ecto-
nucleotidase responsible for the generation of adenosine
and suggest that a putative CD39/CD73-adenosinergic axis
(i.e., generating adenosine) may contribute to the immuno-
regulatory function of Treg (S. Deaglio et al., manuscript
submitted; also Fig. 2).
Adenosine plays a central and direct role in the
regulation of inflammatory responses and limiting inflam-
matory tissue destruction [9, 10, 45]. Potentially, close cell-
cell contacts with pericellular generation of adenosine and
regulated expression of adenosine receptors may be
important modulatory factors directly suppressing T cell
responses. Early in the immune response, adenosine favors
recruitment of DC, which initiates specific immune re-
sponses [9, 10, 28]. The immunosuppressive effects of
adenosine on T cells are thought to be mediated primarily
through the A2A receptor. Adenosine inhibits the produc-
tion of proinflammatory cytokines and superoxide anions.
Adenosine activation of A2A receptor also induces heter-
ologous desensitization of chemokine receptors, which are
critical in leukocyte trafficking, through the activation of
protein kinase A [46].
It is also feasible that the suppression mediated via Treg-
generated adenosine could be exerted indirectly through
downregulation of co-stimulatory molecules on DC or by
competition for other non-characterized signal molecules
[47]. Irrespective of the mechanism of action, we have
shown that FoxP3
+ Tregs are the only T cells that contain
the full enzymatic machinery necessary to generate aden-
osine. This effect, in conjunction with the expression of the
adenosine A2A receptor on effector (CD4
+/CD25
−) T cells,
generates immunosuppressive loops limiting effector cell
proliferation both in vitro and in vivo (S. Deaglio et al.,
submitted).
Immune deviation and autoimmune diathesis
in Cd39-null mice
The pathophysiological relevance of the CD39-adenosinergic
loop was further tested by examining effects of exogenous,
pharmacological adenosine A2A receptor agonists on Tcells,
committed to either Th1 or Th2 lineages [48]. Adenosine
might contribute to the resolution of inflammation by
facilitating Th2 pathways by the inhibition of Th1 cell
functions [49]; this property has been addressed further in
the Cd39-null mice. Subsets of naïve CD4
+ T cells were
polarized to a Th1 or Th2 phenotype through the addition of
IL-12 (10 ng/ml) and anti-IL-4 (10 μg/ml) or IL-4 (10 ng/ml)
and anti-IFN-+ (10 μg/ml), respectively, following stimula-
tion with plate-bound anti-CD3 (5 μg/ml) and soluble anti-
CD28 (2.5 μg/ml). The polarization of cells was confirmed
by intracellular cytokine staining and gene profiling via RT-
PCR analysis.
Heightened expression of the A2A receptor, as measured
by RT-PCR, could be detected in CD4
+/CD25
− cells
polarized in vitro to Th1, but not Th2, phenotypes at day
3 (not shown). In keeping with this observation, the
addition of the adenosine A2A receptor agonist, ATL146e
(kind gift from J. Linden, Adenosine Therapeutics), at day
3 of culture, when all cells are already committed to either a
Th1 or Th2 phenotype, selectively inhibits Th1 prolifera-
tion. This suggests once more that the A2A receptor is the
critical immunomodulatory adenosine receptor [9]. No
inhibition of the Th2 proliferation response by ATL146e
[50] could be noted (Fig. 3a).
Consistent with these results, in vitro polarization of
CD4
+ T cells towards a Th1 phenotype results in the
increased production of IFN-+ by Cd39-null T cells, with a
Th1-deviated phenotype (Fig. 3b). Addition of ATL146e
[50], or soluble NTPDases (apyrase), strongly inhibits the
Th1 response in both the wild-type and Cd39-null polarized
cells confirming that A2A receptors are present and
functional in both groups. These data suggest lack of
substrate in the Cd39-null cells to be responsible for the
observed Th1 bias (Fig. 3c). The A2A antagonist 8-
(3-chloro-styryl) caffeine was shown to augment IFN-γ
production in wild-type cells polarized to a Th1 phenotype
(Fig. 3c), further supporting this hypothesis. In addition,
reconstitution of Cd39-null cells with apyrase restores the
catalytic potential of the cells, producing adenosine and
inhibiting IFN-+ production in a dose-dependent manner,
effects similar to that of ATL146e (Fig. 3d).
Additional evidence that the perturbation in adenosine
generation causes Th1 deviation, is that Cd39-null mice
spontaneously develop autoimmune alopecia. Fifteen per
cent (9/59) of designated Cd39-null animals develop skin
lesions characterized by extensive and well-demarcated hair
loss (Fig. 3e). No lesions are observed in age-matched WT
controls (0/28). Similar lesions were observed in Cd39-null
mice on the BALB/c background suggesting that the
phenotype is strain independent (Fig. 3e). The alopecia
typically appears at ~20–40 weeks of age in the facial
region and thereafter extends out to include the trunk. The
skin lesions are characterized by the presence of a
population of CD4
+ and CD8
+ lymphocytes within the
damaged hair follicles (Fig. 3e). Moreover, sixfold increases
in IFN-+ transcript levels are noted in areas of skin with
active disease, when compared to areas of uninvolved skin
from the same animal or from wild type controls (Fig. 3f).In
178 Purinergic Signalling (2007) 3:171–180addition, there is increased expression of IL-2, Foxp3 and
CTLA-4, consistent with the cellular infiltration. IL-4 and
IL-10 were not detected (Fig. 3f). Autoimmune manifes-
tations impacting other organ systems and on renal function
are under evaluation (D. Friedman, not shown).
These data validate the importance of adenosine in
directing T cell subset differentiation and support a role for
CD39 in orchestrating Treg cell suppressive responses
under both in vitro and in vivo conditions.
Summation
This review summarizes components of extracellular
nucleotide-mediated signalling pathway in T cells that are
impacted upon largely by CD39, the prototypic member of
the E-NTPDase family of ecto-nucleotidases. Modulated,
distinct NTPDase expression appears to regulate nucleo-
tide- and nucleoside-mediated signalling in the immune
system. As the vasculature uses similar mediators to
regulate blood fluidity and hemostasis, expression of
CD39 on either endothelial or immune cells might allow
for full integration of vascular inflammatory and immune
cell reactions at sites of injury.
There is a wide field for future investigations of the role
of nucleotides, nucleosides and ecto-nucleotidases in
immune-mediated diseases. Increasing interest in this field
may open up new avenues for investigation and the
development of new treatment modalities for a large variety
of illnesses, including atherosclerosis and the vascular or
immune inflammation seen in transplant-related diseases.
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